BioSpace News Archive

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced financial results for the second quarter ended June 30, 2023 and provided an update on clinical and corporate developments.

2seventy bio, Inc . (Nasdaq: TSVT), a leading immune-oncology cell therapy company, will announce its second quarter 2023 financial results on Monday, August 14, 2023.

908 Devices Inc. today reported financial results for the quarter ended June 30, 2023.

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the second quarter and six months ended June 30, 2023 and corporate highlights.

Horizon Therapeutics plc Reports Second-Quarter 2023 Financial Results.

CorMedix Inc. today announced financial results for the second quarter and six months ended June 30, 2023 and provided an update on recent business events.

Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today reported financial results for the second quarter ended June 30, 2023, and provided a corporate update.

Mersana Therapeutics, Inc. today provided a business update and reported financial results for the second quarter ended June 30, 2023.

Nasus Pharma Ltd a clinical-stage biopharmaceutical company focused on developing needle-free, powder-based Intranasal (PBI) product portfolio, to address acute medical conditions announced the publication of positive results from a clinical study of intranasal powder-based Epinephrine.

Rallybio Corporation (Nasdaq: RLYB) today reported financial results for the second quarter ended June 30, 2023 and provided an update on recent program and corporate developments.